Pulmatrix Inc
2PU
Company Profile
Business description
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
Contact
945 Concord Street
Suite 1217
FraminghamMA01701
USAT: +1 888 355-4440
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
Does this bank have what it takes to compete with the big 4?
Organic growth and a recent acquisition were the focus of their investor day.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,892.40 | 3.70 | -0.04% |
| CAC 40 | 8,108.43 | 6.31 | -0.08% |
| DAX 40 | 24,046.01 | 17.87 | 0.07% |
| Dow JONES (US) | 47,739.32 | 215.67 | -0.45% |
| FTSE 100 | 9,645.09 | 21.92 | -0.23% |
| HKSE | 25,765.36 | 319.72 | -1.23% |
| NASDAQ | 23,545.90 | 32.22 | -0.14% |
| Nikkei 225 | 50,581.94 | 90.07 | 0.18% |
| NZX 50 Index | 13,483.45 | 2.87 | -0.02% |
| S&P 500 | 6,846.51 | 23.89 | -0.35% |
| S&P/ASX 200 | 8,603.30 | 3.10 | -0.04% |
| SSE Composite Index | 3,924.08 | 21.27 | 0.55% |